Special Issue "10th Anniversary of Biomedicines: Mechanisms and Novel Therapeutic Approaches for Brain Cancer"
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 10225
Interests: pharmacotherapeutics; genome instability; DNA repair; neuro-oncology; system biology; biomarkers
Special Issues, Collections and Topics in MDPI journals
Diffuse glioma is a devastating cancer of the brain, with a documented history of low survival rates. While a tumor of this malignant nature has undergone extensive molecular characterization, the current approach of genomic-informed precision medicine has largely failed to provide a long-term benefit. This questions the ability of using our approach to interpret current data for targeted therapy. The gradual shift from analyzing gene signatures to non-linear machine learning can aid in modeling the complex behavior of glioma. Importantly, an analytical system must facilitate an overall view of the molecular characteristics of different tumors, while continuing to incorporate patient data that can assist in the development of new druggable approaches. As we continue to understand the physiologic mechanisms of glioma, advancements in data interpretation will decipher the composition and functional landscape of tumor heterogeneity. The ultimate goal is to improve patient outcomes, without the risk of disease relapse.
It is our great pleasure to welcome clinicians and scientists to submit their original research work and/or review articles to be considered for publication in this Special Issue. The manuscript should focus on aspects of the development of novel, diagnostic, therapeutic targeting and molecular mechanisms of diffuse glioma in adult and pediatric settings, including, but not limited to, the following subtopics:
- Biomarkers for monitoring disease progression;
- Radiomics strategy for tumor grading;
- Consequences of genome instability and DNA repair deficiencies;
- Influence of the tumor immune microenvironment;
- Chromatin modifications in promoting tumor malignancy;
- Novel biomaterials for drug delivery;
- Biological underpinnings of therapeutic resistance;
- Use of omics technologies to optimize the development of targeted therapies.
Dr. Yi Chieh Lim
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- genomic instability
- DNA repair
- precision medicine
- therapeutic resistance
- computational biology
- drug delivery
- medical imaging